<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881556</url>
  </required_header>
  <id_info>
    <org_study_id>AAAD5420</org_study_id>
    <secondary_id>CHNY-08-536</secondary_id>
    <nct_id>NCT00881556</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)</brief_title>
  <acronym>RDEB</acronym>
  <official_title>A Pilot Study of Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLOSCT) In Children With Recessive Dystrophic Epidermolysis Bullosa (RDEB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (AlloSCT) from&#xD;
      family-related donors and unrelated cord blood (UCB) donors will be safe and well tolerated&#xD;
      in selected patients with RDEB.&#xD;
&#xD;
      To determine the event-free survival (EFS) and overall survival (OS) following RIC consisting&#xD;
      of busulfan/fludarabine/alemtuzumab (BFA) and AlloSCT in selected patients with RDEB.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidermolysis bullosa (EB), is a diverse group of genodermatoses, which is considered a rare&#xD;
      and orphan disease and affects approximately 1 in 20,000 people in the United States for a&#xD;
      cumulative total of close to 20,000[1-4]. There are three major subtypes of inherited EB,&#xD;
      including EB simplex (EBS), junctional EB (JEB), and dystrophic EB[1-4]. RDEB is among the&#xD;
      most severe and represents approximately 10% of all forms of EB[1-4]. A rough estimate would&#xD;
      then project that there are several thousand patients with RDEB in the U.S. at the current&#xD;
      time. Up to 30 different clinical phenotypes and mutations in at least 10 structural genes in&#xD;
      different sub-types of EB have been reported[4-8]. In addition to heritable subtypes of EB,&#xD;
      there is an acquired autoimmune form in which the patients develop auto-antibodies directed&#xD;
      against similar proteins of the inherited dystrophic forms of EB, including EB acquisita&#xD;
      (EBA).&#xD;
&#xD;
      We have previously reported our experience with RIC with BFA [48] in pediatric AlloSCT&#xD;
      recipients (mean age 9.5 yrs [1.4-21], 11/4 M/F, 10 non-malignant, 5 malignant disease, [6&#xD;
      sibling, 5 UCB, 5 matched unrelated donor]); median time to ANC ≥ 500/mm3 and platelet count&#xD;
      ≥20K/mm3 was 22 and 30 days, respectively. Probability of day +180 and 365 donor chimerism&#xD;
      was 90% (Figure 7), and OS was 95% (Figure 8). This conditioning regimen therefore results in&#xD;
      a high degree of donor chimerism and survival with minimal regimen related mortality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">August 20, 2009</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of whole blood (CD45), T-cell (CD3), and NK cell (CD56) chimerism following RIC and AlloSCT in selected patients with RDEB</measure>
    <time_frame>Up to Day +730</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of donor skin dermal chimerism following RIC and AlloSCT in selected patients with RDEB.</measure>
    <time_frame>Up to Day +730</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>RIC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reduced Intensity Transplant Conditioning (RIC):&#xD;
Palifermin (Kepivance®) 60 mcg/kg/day for 6 days Fludarabine 30 mg/m2 IV x 1 for 6 days Busulfan 4 mg/kg/day IV divided BID for 4 days Lorazepam 0.02-0.05 mg/kg for 5 days Alemtuzumab 20 mg/m2 IV for 5 days Tacrolimus 0.03mg/kg/24 hours as continuous infusion for 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palifermin</intervention_name>
    <description>60 mcg/kg/day for 6 days</description>
    <arm_group_label>RIC Group</arm_group_label>
    <other_name>Kepivance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2 IV x 1 for 6 days</description>
    <arm_group_label>RIC Group</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>4 mg/kg/day IV divided BID for 4 days</description>
    <arm_group_label>RIC Group</arm_group_label>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam</intervention_name>
    <description>0.02-0.05 mg/kg for 5 days</description>
    <arm_group_label>RIC Group</arm_group_label>
    <other_name>Ativan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>20 mg/m2 IV for 5 days</description>
    <arm_group_label>RIC Group</arm_group_label>
    <other_name>Lemtrada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>0.03mg/kg/24 hours as continuous infusion for 4 days</description>
    <arm_group_label>RIC Group</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
    <other_name>Hecoria</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recessive Dystrophic Epidermolysis Bullosa (RDEB)&#xD;
&#xD;
          -  Diagnosis of RDEB using molecular diagnosis and sequencing of mutations&#xD;
&#xD;
          -  Skin biopsy to determine status of type VII collagen&#xD;
&#xD;
          -  Age ≤21 years&#xD;
&#xD;
          -  Patient must have adequate organ function as below:&#xD;
&#xD;
               1. Adequate renal function defined as:&#xD;
&#xD;
                    -  Serum creatinine less than or equal to 1.5 x normal, or&#xD;
&#xD;
                    -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) =40&#xD;
                       ml/min/m2 or &gt; 60 ml/min/1.73 m2 or an equivalent GFR as determined by the&#xD;
                       institutional normal range&#xD;
&#xD;
               2. Adequate liver function defined as:&#xD;
&#xD;
                    -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase&#xD;
                       (AST)) or serum glutamic-pyruvic transaminase (SGPT) (alanine&#xD;
                       aminotransferase (ALT))&lt; 5.0 x normal&#xD;
&#xD;
               3. Adequate cardiac function defined as:&#xD;
&#xD;
                    -  Shortening fraction of ≥28% by echocardiogram, or&#xD;
&#xD;
                    -  Ejection fraction of ≥48% by radionuclide angiogram or echocardiogram&#xD;
&#xD;
               4. Adequate pulmonary function defined as:&#xD;
&#xD;
                    -  Uncorrected diffusing capacity of the lungs for carbon monoxide (DLCO) ≥35%&#xD;
                       by pulmonary function test&#xD;
&#xD;
                    -  For children who are uncooperative, no evidence of dyspnea at rest&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Karnofsky/Lansky Performance Score &lt;50%&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Uncontrolled bacterial, viral or mold infection&#xD;
&#xD;
          -  History or presence of skin squamous cell carcinoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Christiano, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morgan Stanley Children's Hospital of NYP</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 14, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic Stem Cell Transplant</keyword>
  <keyword>AlloSCT</keyword>
  <keyword>RDEB</keyword>
  <keyword>recessive dystrophic epidermolysis bullosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Lorazepam</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

